Intellia Therapeutics Inc.

41.63+3.00+7.77%Vol 1.12M1Y Perf -53.12%
Jan 27th, 2023 16:00 DELAYED
BID41.78 ASK42.00
Open38.44 Previous Close38.63
Pre-Market- After-Market41.82
 - -  0.19 0.46%
Target Price
109.30 
Analyst Rating
Strong Buy 1.36
Potential %
162.55 
Finscreener Ranking
★★★+     52.07
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★     51.46
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★+     54.55
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
12.69 
Earnings Rating
Strong Buy
Market Cap3.59B 
Earnings Date
23rd Feb 2023
Alpha0.03 Standard Deviation0.25
Beta1.97 

Today's Price Range

38.4441.70

52W Range

32.44104.87

5 Year PE Ratio Range

-18.20-9.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
22.98%
1 Month
24.42%
3 Months
-22.95%
6 Months
-36.60%
1 Year
-53.12%
3 Years
209.52%
5 Years
68.47%
10 Years
-

TickerPriceChg.Chg.%
NTLA41.633.00007.77
AAPL145.931.97001.37
GOOG100.711.55001.56
MSFT248.150.15000.06
XOM115.61-2.1500-1.83
WFC46.120.31000.68
JNJ168.23-0.6600-0.39
FB196.640.99000.51
GE83.232.09002.58
JPM140.320.34000.24
 
ProfitabilityValueIndustryS&P 500US Markets
-
-833.60
-819.20
-326.70
-
RevenueValueIndustryS&P 500US Markets
38.55M
0.45
0.07
13.13
Earnings HistoryEstimateReportedSurprise %
Q03 2022-1.31-1.49-13.74
Q02 2022-1.31-1.33-1.53
Q01 2022-1.11-1.96-76.58
Q04 2021-0.91-1.09-19.78
Q03 2021-0.85-0.97-14.12
Q02 2021-0.61-1.01-65.57
Q01 2021-0.66-0.69-4.55
Q04 2020-0.57-0.69-21.05
Earnings Per EndEstimateRevision %Trend
12/2022 QR-1.1410.94Positive
12/2022 FY-6.03-3.61Negative
3/2023 QR-1.42-7.58Negative
12/2023 FY-5.87-1.21Negative
Next Report Date23rd Feb 2023
Estimated EPS Next Report-1.38
Estimates Count14
EPS Growth Next 5 Years %13.20
Volume Overview
Volume1.12M
Shares Outstanding86.22K
Shares Float66.03M
Trades Count20.72K
Dollar Volume45.59M
Avg. Volume1.20M
Avg. Weekly Volume1.34M
Avg. Monthly Volume1.12M
Avg. Quarterly Volume1.12M

Intellia Therapeutics Inc. (NASDAQ: NTLA) stock closed at 41.63 per share at the end of the most recent trading day (a 7.77% change compared to the prior day closing price) with a volume of 1.12M shares and market capitalization of 3.59B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 312 people. Intellia Therapeutics Inc. CEO is John M. Leonard.

The one-year performance of Intellia Therapeutics Inc. stock is -53.12%, while year-to-date (YTD) performance is 19.32%. NTLA stock has a five-year performance of 68.47%. Its 52-week range is between 32.435 and 104.87, which gives NTLA stock a 52-week price range ratio of 12.69%

Intellia Therapeutics Inc. currently has a PE ratio of -6.50, a price-to-book (PB) ratio of 3.94, a price-to-sale (PS) ratio of 81.39, a price to cashflow ratio of 17.80, a PEG ratio of 2.32, a ROA of -39.90%, a ROC of -42.33% and a ROE of -50.15%. The company’s profit margin is -%, its EBITDA margin is -819.20%, and its revenue ttm is $38.55 Million , which makes it $0.45 revenue per share.

Of the last four earnings reports from Intellia Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.38 for the next earnings report. Intellia Therapeutics Inc.’s next earnings report date is 23rd Feb 2023.

The consensus rating of Wall Street analysts for Intellia Therapeutics Inc. is Strong Buy (1.36), with a target price of $109.3, which is +162.55% compared to the current price. The earnings rating for Intellia Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Intellia Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Intellia Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.46, ATR14 : 2.46, CCI20 : 171.59, Chaikin Money Flow : 0.25, MACD : -0.21, Money Flow Index : 55.77, ROC : 10.10, RSI : 60.32, STOCH (14,3) : 99.24, STOCH RSI : 1.00, UO : 67.84, Williams %R : -0.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Intellia Therapeutics Inc. in the last 12-months were: David Lebwohl (Option Excercise at a value of $0), Glenn Goddard (Option Excercise at a value of $0), John M. Leonard (Option Excercise at a value of $0), Laura Sepp-Lorenzino (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
16 (76.19 %)
15 (75.00 %)
15 (75.00 %)
Moderate Buy
2 (9.52 %)
2 (10.00 %)
2 (10.00 %)
Hold
3 (14.29 %)
2 (10.00 %)
2 (10.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
1 (5.00 %)
1 (5.00 %)
Summary RatingStrong Buy
1.36
Strong Buy
1.48
Strong Buy
1.48

Intellia Therapeutics Inc.

Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.

CEO: John M. Leonard

Telephone: +1 857 285-6200

Address: 40 Erie Street, Cambridge 02139, MA, US

Number of employees: 312

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

63%37%

Bearish Bullish

60%40%

TipRanks News for NTLA

Mon, 23 Jan 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Intellia Therapeutics (NTLA) and Marinus (MRNS)

- TipRanks. All rights reserved.

Mon, 09 Jan 2023 04:15 GMT Intellia Therapeutics (NTLA) Has a New Rating from SVB Securities

- TipRanks. All rights reserved.

Mon, 19 Sep 2022 12:45 GMT Intellia Therapeutics (NTLA) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Fri, 16 Sep 2022 21:05 GMT Intellia Therapeutics (NTLA) Receives a Buy from Chardan Capital

- TipRanks. All rights reserved.

Fri, 05 Aug 2022 12:35 GMT Intellia Therapeutics (NTLA) Receives a Hold from BMO Capital

- TipRanks. All rights reserved.

Fri, 05 Aug 2022 04:53 GMT Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Bicycle Therapeutics (BCYC) and OrthoPediatrics (KIDS)

- TipRanks. All rights reserved.

Thu, 04 Aug 2022 22:45 GMT Intellia Therapeutics (NTLA) Gets a Buy Rating from Chardan Capital

- TipRanks. All rights reserved.

News

Stocktwits